In recent days, Insmed reported strong early physician conviction and broad prescribing intent for its newly launched drug brensocatib, alongside continued positive safety data and a fresh round of ...

Why Insmed Stock Is Back on Investors’ Radar Insmed (INSM) has drawn fresh attention after a period of weaker share performance, with the stock down 20% over the past month and 28% over the past 3 ...

UBS analyst Ashwani Verma reiterated a Buy rating on Insmed yesterday and set a price target of $166.00. The company’s shares closed yesterday at $103.86. Claim 55% Off TipRanks ...

Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Mid Cap Growth Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the ...

Investors in Insmed Inc (Symbol: INSM) saw new options begin trading today, for the October 17th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the ...

As of January 14, 2026, the average one-year price target for Insmed is $217.87/share. The forecasts range from a low of $158.57 to a high of $253.05. The average price target represents an increase ...

Drug maker Insmed (INSM) is rising 6% today after it released on Friday afternoon its estimate of the revenue generated by its Arikayce drug in 2024. The company also provided 2025 sales guidance for ...

We recently compiled a list of the 20 Large-Cap Stocks Insiders and Short Sellers Are Dumping Like Crazy. In this article, we are going to take a look at where Insmed Incorporated (NASDAQ:INSM) stands ...

William Blair initiated coverage on Insmed Incorporated (NASDAQ:INSM), citing that the clinical and commercial execution of its drugs can significantly increase Insmed's valuation. “While ...

Barclays analyst Eliana Merle maintained a Buy rating on Insmed today and set a price target of $237.00. Memorial Day Sale – Claim 70% Off TipRanks. Unlock trusted, data-backed ...